Is the Fast Track Safe? A Safety Evaluation of the COVID-19 Drugs with Real-World Data

被引：0

作者：

Kim, Hyo Jung ^{[1
,2
]}

Yoon, Jeong-Hwa ^{[3
]}

Lee, Kyehwa ^{[4
]}

机构：

[1] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Digital Hlth, Seoul, South Korea

[2] Samsung Med Ctr, Res Inst Future Med, Ctr Res Resource Standardizat, Seoul, South Korea

[3] Seoul Natl Univ, Inst Hlth Policy & Management, Med Res Ctr, Seoul, South Korea

[4] Asan Med Ctr, Dept Med Informat, Seoul, South Korea

来源：

MEDINFO 2023 - THE FUTURE IS ACCESSIBLE | 2024年 / 310卷

基金：

新加坡国家研究基金会;

关键词：

COVID-19; adverse drug reaction; post-market surveillance; FDA adverse event reporting system;

D O I：

10.3233/SHTI231256

中图分类号：

TP18 [人工智能理论];

学科分类号：

081104 ; 0812 ; 0835 ; 1405 ;

摘要：

The US FDA has given emergency use authorization to multiple Covid19 drugs. We conducted disproportionality analysis to detect adverse reaction rates (ADRs) in the US FDA's Adverse Event Reporting System. We discovered not only severe ADRs but also unique ADRs and effectiveness that might be explained by pharmacokinetics. This shows that real-time safety reviews could be effective methods for comparing the safety and efficacy of fast-track authorized drugs.

引用

页码：1484 / 1485

页数：2

共 50 条

[1] Leveraging Real-World Data in COVID-19 Response
Cooner, Freda
Liao, Ran
Lin, Junjing
Barthel, Sophie
Seifu, Yodit
Ruan, Shiling
STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2023, 15 (03): : 582 - 595
[2] Evaluation of favipiravir in the treatment of COVID-19 based on the real-world
Deng, Weishang
Yang, Changyuan
Yang, Sensen
Chen, Haitao
Qiu, Zhikun
Chen, Jisheng
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2022, 20 (04) : 555 - 565
[3] Biases in Evaluating the Safety and Effectiveness of Drugs for the Treatment of COVID-19: Designing Real-World Evidence Studies
Renoux, Christel
Azoulay, Laurent
Suissa, Samy
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2021, 190 (08) : 1452 - 1456
[4] Real-world prescription of anti-COVID-19 drugs in hospitalized patients with COVID-19 in Japan
Shida, Haruka
Komamine, Maki
Kajiyama, Kazuhiro
Waki, Takashi
Maruyama, Hotaka
Uyama, Yoshiaki
PLOS ONE, 2024, 19 (01):
[5] Adverse events associated with potential drugs for COVID-19: a case study from real-world data
Jing, Ying
Diao, Lixia
Han, Leng
BRIEFINGS IN BIOINFORMATICS, 2021, 22 (02) : 1232 - 1238
[6] Anti-rheumatic drugs for COVID-19: A real-world experience with baricitinib
Ahmed, Mania
Lee, Lit Hiang
RESPIROLOGY, 2023, 28 : 206 - 206
[7] Evaluating real-world data in COVID-19 antigen and PCR testing
Rose, Olaf
Obarcanin, Emina
Erzkamp, Susanne
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2023, 61 (04) : 172 - 177
[8] Real-World Data on the Impact of COVID-19 on Endoscopic Procedural Delays
Issaka, Rachel B.
Feld, Lauren D.
Kao, Jason
Hegarty, Erin
Snailer, Brandon
Kalra, Gorav
Tomizawa, Yutaka
Strate, Lisa
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2021, 12 (06) : E00365
[9] COVID-19 real-world data for the US and lessons to reopen business
Goldschmidt-Clermont, Pascal J.
PLOS PATHOGENS, 2020, 16 (08)
[10] COVID-19 confidential: Enabling trust in COVID-19 research with fit for purpose real-world data
Gatto, Nicolle M.
Franklin, Jessica
Garry, Elizabeth M.
Martin, David
Chakravarty, Aloka
Rassen, Jeremy A.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 6 - 6

← 1 2 3 4 5 →